,i #aafth ,,congress #b;d ,session ,h4 ,r4 #ehhb ,,in ,,the ,,house ,,of ,,representatives ,february #ab1 #bjbj,mr4 ,schrader 7for himself1 ,mr4 ,marshall1 ,mr4 ,crow1 ,mr4 ,mullin1 ,mr4 ,bera1 ,mr4 ,kelly of ,pennsylvania1 and ,mr4 ,schweikert7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend title ,,xix of the ,social ,security ,act to provide ,states with the option under the ,medicaid program to pay for covered outpatient drugs through risk-sharing value-based agreements1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,generating ,effective and ,novel ,evidence for ,therapy ,payment ,act or ,,gene ,therapy ,payment ,act4 #b4 ,risk-sharing value-based payment agreements for covered outpatient drugs under ,medicaid 7a7 ,in general ,section #aibg of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7 is amended by adding at the end the following new subsection3 7l7 ,state option ,to pay for covered outpatient drugs through risk-,sharing value-,based agreements 7#a7 ,in general ,beginning ,january #a1 #bjbb1 a ,state shall have the option to pay 7whether on a fee-for-service or managed care basis7 for covered outpatient drugs that are potentially curative treatments intended for one-time use that are administered to individuals under this title by entering into a risk-sharing value-based payment agreement with the manufacturer of the drug in accordance with the requirements of this subsection4 7#b7 ,secretarial approval 7,a7 ,in general ,a ,state shall submit a request to the ,secretary to enter into a risk-sharing value-based payment agreement1 and the ,secretary shall not approve a proposed risk-sharing value-based payment agreement between a ,state and a manufacturer for payment for a covered outpatient drug of the manufacturer unless the following requirements are met3 7i7 ,manufacturer has in effect a rebate agreement and is in compliance with all applicable requirements ,the manufacturer has a rebate agreement in effect as required under subsections 7a7 and 7b7 of this section and is in compliance with all applicable requirements under this title4 7ii7 ,no increase to projected net ,federal spending 7,i7 ,in general ,the ,chief ,actuary certifies that the projected payments for each covered outpatient drug under a proposed risk-sharing value-based payment agreement is not expected to result in greater estimated ,federal spending under this title than the net ,federal spending that would result in the absence of such agreement4 7,,ii7 ,net federal spending defined ,for purposes of this subsection1 the term net ,federal spending means the amount of ,federal payments the ,chief ,actuary estimates would be made under this title for administering a covered outpatient drug to an individual eligible for medical assistance under a ,state plan or a waiver of such plan1 reduced by the amount of all rebates the ,chief ,actuary estimates would be paid with respect to the administering of such drug1 including all rebates under this title and any supplemental or other additional rebates1 in the absence of such an agreement4 7,,iii7 ,information ,the ,chief ,actuary shall make the certifications required under this clause based on the most recently available and reliable drug pricing and product information4 ,the ,state and manufacturer shall provide the ,secretary and the ,chief ,actuary with all necessary information required to make the estimates needed for such certifications4 7iii7 ,launch and list price justifications ,the manufacturer submits all relevant information and supporting documentation necessary for pricing decisions as deemed appropriate by the ,secretary1 which shall be truthful and non-misleading1 including manufacturer information and supporting documentation for launch price or list price increases1 and any applicable justification required under section #aabh,l4 7iv7 ,confidentiality of information2 penalties ,the provisions of subparagraphs 7,c7 and 7,d7 of subsection 7b77#c7 shall apply to a manufacturer that fails to submit the information and documentation required under clauses 7ii7 and 7iii7 on a timely basis1 or that knowingly provides false or misleading information1 in the same manner as such provisions apply to a manufacturer with a rebate agreement under this section4 7,b7 ,consideration of ,state request for approval 7i7 ,in general ,the ,secretary shall treat a ,state request for approval of a risk-sharing value-based payment agreement in the same manner that the ,secretary treats a ,state plan amendment1 and subpart ,b of part #dcj of title #db1 ,code of ,federal ,regulations1 including1 subject to clause 7ii71 the timing requirements of section #dcj4af of such title 7as in effect on the date of enactment of this subsection71 shall apply to a request for approval of a risk-sharing value-based payment agreement in the same manner as such subpart applies to a ,state plan amendment4 7ii7 ,timing ,the ,secretary shall consult with the ,commissioner of ,food and ,drugs as required under subparagraph 7,c7 and make a determination on whether to approve a request from a ,state for approval of a proposed risk-sharing value-based payment agreement 7or request additional information necessary to allow the ,secretary to make a determination with respect to such request for approval7 within the time period1 to the extent practicable1 specified in section #dcj4af of title #db1 ,code of ,federal ,regulations 7as in effect on the date of enactment of this subsection71 but in no case shall the ,secretary take more than #ahj days after the receipt of such request for approval or response to such request for additional information to make such a determination 7or request additional information74 7,c7 ,consultation with the ,commissioner of ,food and ,drugs ,in considering whether to approve a risk-sharing value-based payment agreement1 the ,secretary1 to the extent necessary1 shall consult with the ,commissioner of ,food and ,drugs to determine whether the relevant clinical parameters specified in such agreement are appropriate4 7#c7 ,installment-based payment structure 7,a7 ,in general ,a risk-sharing value-based payment agreement shall provide for a payment structure under which1 for every installment year of the agreement 7subject to subparagraph 7,b771 the ,state shall pay the total installment year amount in equal installments to be paid at regular intervals over a period of time that shall be specified in the agreement4 7,b7 ,requirements for installment payments 7i7 ,timing of first payment ,the ,state shall make the first of the installment payments described in subparagraph 7,a7 for an installment year not later than #cj days after the end of such year4 7ii7 ,length of installment period ,the period of time over which the ,state shall make the installment payments described in subparagraph 7,a7 for an installment year shall not be longer than #e years4 7iii7 ,nonpayment or reduced payment of installments following a failure to meet clinical parameter ,if1 prior to the payment date 7as specified in the agreement7 of any installment payment described in subparagraph 7,a7 or any other alternative date or time frame 7as otherwise specified in the agreement71 the covered outpatient drug which is subject to the agreement fails to meet a relevant clinical parameter of the agreement1 the agreement shall provide that-- 7,i7 the installment payment shall not be made2 or 7,,ii7 the installment payment shall be reduced by a percentage specified in the agreement that is based on the outcome achieved by the drug relative to the relevant clinical parameter4 7#d7 ,notice of intent 7,a7 ,in general ,subject to subparagraph 7,b71 a manufacturer of a covered outpatient drug shall not be eligible to enter into a risk-sharing value-based payment agreement under this subsection with respect to such drug unless the manufacturer notifies the ,secretary that the manufacturer is interested in entering into such an agreement with respect to such drug4 ,the decision to submit and timing of a request to enter into a proposed risk-sharing value-based payment agreement shall remain solely within the discretion of the ,state and shall only be effective upon ,secretarial approval as required under this subsection4 7,b7 ,treatment of subsequently approved drugs 7i7 ,in general ,in the case of a manufacturer of a covered outpatient drug approved under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act or licensed under section #cea of the ,public ,health ,service ,act after the date of enactment of this subsection1 not more than #ij days after meeting with the ,food and ,drug ,administration following phase ,,ii clinical trials for such drug 7or1 in the case of a drug described in clause 7ii71 not later than ,march #ca1 #bjbb71 the manufacturer must notify the ,secretary of the manufacturer's intent to enter into a risk-sharing value-based payment agreement under this subsection with respect to such drug4 ,if no such meeting has occurred1 the ,secretary may use discretion as to whether a potentially curative treatment intended for one-time use may qualify for a risk-sharing value-based payment agreement under this section4 ,a manufacturer notification of interest shall not have any influence on a decision for drug approval by the ,food and ,drug ,administration4 7ii7 ,application to certain subsequently approved drugs ,a drug described in this clause is a covered outpatient drug of a manufacturer-- 7,i7 that is approved under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act or licensed under section #cea of the ,public ,health ,service ,act after the date of enactment of this subsection2 and 7,,ii7 with respect to which1 as of ,january #a1 #bjbb1 more than #ij days have passed after the manufacturer's meeting with the ,food and ,drug ,administration following phase ,,ii clinical trials for such drug4 7iii7 ,parallel approval ,the ,secretary1 in coordination with the ,administrator of the ,centers for ,medicare ,medicaid ,services and the ,commissioner of ,food and ,drugs1 shall1 to the extent practicable1 approve a ,state's request to enter into a proposed risk-sharing value-based payment agreement that otherwise meets the requirements of this subsection at the time that such a drug is approved by the ,food and ,drug ,administration to help provide that no ,state that wishes to enter into such an agreement is required to pay for the drug in full at one time if the ,state is seeking to pay over a period of time as outlined in the proposed agreement4 7iv7 ,rule of construction ,nothing in this paragraph shall be applied or construed to modify or affect the timeframes or factors involved in the ,secretary's determination of whether to approve or license a drug under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act or section #cea of the ,public ,health ,service ,act4 7#e7 ,special payment rules 7,a7 ,in general ,except as otherwise provided in this paragraph1 with respect to an individual who is administered a unit of a covered outpatient drug that is reimbursed under a ,state plan by a ,state ,medicaid agency under a risk-sharing value-based payment agreement in an installment year1 the ,state shall remain liable to the manufacturer of such drug for payment for such unit without regard to whether the individual remains enrolled in the ,state plan under this title 7or a waiver of such plan7 for each installment year for which the ,state is to make installment payments for covered outpatient drugs purchased under the agreement in such year4 7,b7 ,death ,in the case of an individual described in subparagraph 7,a7 who dies during the period described in such subparagraph1 the ,state plan shall not be liable for any remaining payment for the unit of the covered outpatient drug administered to the individual which is owed under the agreement described in such subparagraph4 7,c7 ,withdrawal of approval ,in the case of a covered outpatient drug that is the subject of a risk-sharing value-based payment agreement between a ,state and a manufacturer under this subsection1 including a drug approved in accordance with section #ejf7;c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 and such drug is the subject of an application that has been withdrawn by the ,secretary1 the ,state plan shall not be liable for any remaining payment that is owed under the agreement4 7,d7 ,alternative arrangement under agreement ,subject to approval by the ,secretary1 the terms of a proposed risk-sharing value-based payment agreement submitted for approval by a ,state may provide that subparagraph 7,a7 shall not apply4 7,e7 ,guidance ,not later than ,january #a1 #bjbb1 the ,secretary shall issue guidance to ,states establishing a process for ,states to notify the ,secretary when an individual who is administered a unit of a covered outpatient drug that is purchased by a ,state plan under a risk-sharing value-based payment agreement ceases to be enrolled under the ,state plan under this title 7or a waiver of such plan7 or dies before the end of the installment period applicable to such unit under the agreement4 7#f7 ,treatment of payments under risk-sharing value-based agreements for purposes of average manufacturer price2 best price ,the ,secretary shall treat any payments made to the manufacturer of a covered outpatient drug under a risk-sharing value-based payment agreement under this subsection during a rebate period in the same manner that the ,secretary treats payments made under a ,state supplemental rebate agreement under sections #ddg4ejd7;c77#ai7 and #ddg4eje7;c77#g7 of title #db1 ,code of ,federal ,regulations 7or any successor regulations7 for purposes of determining average manufacturer price and best price under this section with respect to the covered outpatient drug and a rebate period and for purposes of offsets required under subsection 7b77#a77;,b74 7#g7 ,assessments and report to ,congress 7,a7 ,assessments 7i7 ,in general ,not later than #ahj days after the end of each assessment period of any risk-sharing value-based payment agreement for a ,state approved under this subsection1 the ,secretary shall conduct an evaluation of such agreement which shall include an evaluation by the ,chief ,actuary to determine whether program spending under the risk-sharing value-based payment agreement aligned with the projections for the agreement made under paragraph 7#b77;,a77ii71 including an assessment of whether actual ,federal spending under this title under the agreement was less or more than net ,federal spending would have been in the absence of the agreement4 7ii7 ,assessment period ,for purposes of clause 7i7-- 7,i7 the first assessment period for a risk-sharing value-based payment agreement shall be the period of time over which payments are scheduled to be made under the agreement for the first #aj individuals who are administered covered outpatient drugs under the agreement except that such period shall not exceed the #e-year period after the date on which the ,secretary approves the agreement2 and 7,,ii7 each subsequent assessment period for a risk-sharing value-based payment agreement shall be the #e-year period following the end of the previous assessment period4 7,b7 ,results of assessments 7i7 ,termination option ,if the ,secretary determines as a result of the assessment by the ,chief ,actuary under subparagraph 7,a7 that the actual ,federal spending under this title for any covered outpatient drug that was the subject of the ,state's risk-sharing value-based payment agreement was greater than the net ,federal spending that would have resulted in the absence of the agreement1 the ,secretary may terminate approval of such agreement and shall immediately conduct an assessment under this paragraph of any other ongoing risk-sharing value-based payment agreement to which the same manufacturer is a party4 7ii7 ,repayment required 7,i7 ,in general ,if the ,secretary determines as a result of the assessment by the ,chief ,actuary under subparagraph 7,a7 that the ,federal spending under the risk-sharing value-based agreement for a covered outpatient drug that was subject to such agreement was greater than the net ,federal spending that would have resulted in the absence of the agreement1 the manufacturer shall repay the difference to the ,state and ,federal ,governments in a timely manner as determined by the ,secretary4 7,,ii7 ,termination for failure to pay ,the failure of a manufacturer to make repayments required under subclause 7,i7 in a timely manner shall result in immediate termination of all risk-sharing value-based agreements to which the manufacturer is a party4 7,,iii7 ,additional penalties ,in the case of a manufacturer that fails to make repayments required under subclause 7,i71 the ,secretary may treat such manufacturer in the same manner as a manufacturer that fails to pay required rebates under this section1 and the ,secretary may-- 7aa7 suspend or terminate the manufacturer's rebate agreement under this section2 and 7bb7 pursue any other remedy that would be available if the manufacturer had failed to pay required rebates under this section4 7,c7 ,report to congress ,not later than #e years after the first risk-sharing value-based payment agreement is approved under this subsection1 the ,secretary shall submit to ,congress and make available to the public a report that includes-- 7i7 an assessment of the impact of risk-sharing value-based payment agreements on access for individuals who are eligible for benefits under a ,state plan or waiver under this title to medically necessary covered outpatient drugs and related treatments2 7ii7 an analysis of the impact of such agreements on overall ,state and ,federal spending under this title2 7iii7 an assessment of the impact of such agreements on drug prices1 including launch price and price increases2 and 7iv7 such recommendations to ,congress as the ,secretary deems appropriate4 7#h7 ,guidance and regulations 7,a7 ,in general ,not later than ,january #a1 #bjbb1 the ,secretary shall issue guidance to ,states seeking to enter into risk-sharing value-based payment agreements under this subsection that includes a model template for such agreements4 ,the ,secretary may issue any additional guidance or promulgate regulations as necessary to implement and enforce the provisions of this subsection4 7,b7 ,model agreements 7i7 ,in general ,if a ,state expresses an interest in pursuing a risk-sharing value-based payment agreement under this subsection with a manufacturer for the purchase of a covered outpatient drug1 the ,secretary may share with such ,state any risk-sharing value-based agreement between a ,state and the manufacturer for the purchase of such drug that has been approved under this subsection4 ,while such shared agreement may serve as a template for a ,state that wishes to propose1 the use of a previously approved agreement shall not affect the submission and approval process for approval of a proposed risk-sharing value-based payment agreement under this subsection1 including the requirements under paragraph 7#b77;,a74 7ii7 ,confidentiality ,in the case of a risk-sharing value-based payment agreement that is disclosed to a ,state by the ,secretary under this subparagraph and that is only in effect with respect to a single ,state1 the confidentiality of information provisions described in subsection 7b77#c77;,d7 shall apply to such information4 7,c7 ,,oig consultation 7i7 ,in general ,the ,secretary shall consult with the ,office of the ,inspector ,general of the ,department of ,health and ,human ,services to determine whether there are potential program integrity concerns 7including issues related to compliance with sections #aabh;,b and #ahgg7 with agreement approvals or templates and address accordingly4 7ii7 ,,oig policy updates as necessary ,the ,inspector ,general of the ,department of ,health and ,human ,services shall review and update1 as necessary1 any policies or guidelines of the ,office of the ,inspector ,general of the ,department of ,health and ,human ,services 7including policies related to the enforcement of section #aabh;,b7 to accommodate the use of risk-sharing value-based payment agreements in accordance with this section4 7#i7 ,rules of construction 7,a7 ,modifications ,nothing in this subsection or any regulations promulgated under this subsection shall prohibit a ,state from requesting a modification from the ,secretary to the terms of a risk-sharing value-based payment agreement4 ,a modification that is expected to result in any increase to projected net ,state or ,federal spending under the agreement shall be subject to recertification by the ,chief ,actuary as described in paragraph 7#b77;,a77ii7 before the modification may be approved4 7,b7 ,rebate agreements ,nothing in this subsection shall be construed as requiring a ,state to enter into a risk-sharing value-based payment agreement or as limiting or superseding the ability of a ,state to enter into a supplemental rebate agreement for a covered outpatient drug4 7,c7 ,,ffp for payments under risk-sharing value-based payment agreements ,federal financial participation shall be available under this title for any payment made by a ,state to a manufacturer for a covered outpatient drug under a risk-sharing value-based payment agreement in accordance with this subsection1 except that no ,federal financial participation shall be available for any payment made by a ,state to a manufacturer under such an agreement on and after the effective date of a disapproval of such agreement by the ,secretary4 7,d7 ,continued application of other provisions ,except as expressly provided in this subsection1 nothing in this subsection or in any regulations promulgated under this subsection shall affect the application of any other provision of this ,act4 7#aj7 ,appropriations ,for fiscal year #bjbj and each fiscal year thereafter1 there are appropriated to the ,secretary #e1jjj1jjj for the purpose of carrying out this subsection4 7#aa7 ,definitions ,in this subsection3 7,a7 ,chief ,actuary ,the term ,chief ,actuary means the ,chief ,actuary of the ,centers for ,medicare ,medicaid ,services4 7,b7 ,installment year ,the term installment year means1 with respect to a risk-sharing value-based payment agreement1 a #ab-month period during which a covered outpatient drug is administered under the agreement4 7,c7 ,potentially curative treatment intended for one-time use ,the term potentially curative treatment intended for one-time use means a treatment that consists of the administration of a covered outpatient drug that-- 7i7 is a form of gene therapy for a rare disease1 as defined by the ,commissioner of ,food and ,drugs1 designated under section #ebf of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 and approved under section #eje of such ,act or licensed under subsection 7a7 or 7k7 of section #cea of the ,public ,health ,service ,act to treat a serious or life-threatening disease or condition2 7ii7 if administered in accordance with the labeling of such drug1 is expected to result in either-- 7,i7 the cure of such disease or condition2 or 7,,ii7 a reduction in the symptoms of such disease or condition to the extent that such disease or condition is not expected to lead to early mortality2 and 7iii7 is expected to achieve a result described in clause 7ii71 which may be achieved over an extended period of time1 after not more than #c administrations4 7,d7 ,relevant clinical parameter ,the term relevant clinical parameter means1 with respect to a covered outpatient drug that is the subject of a risk-sharing value-based payment agreement-- 7i7 a clinical endpoint specified in the drug's labeling or supported by one or more of the compendia described in section #ahfa7t77#b77;,b77ii77,i7 that-- 7,i7 is able to be measured or evaluated on an annual basis for each year of the agreement on an independent basis by a provider or other entity2 and 7,,ii7 is required to be achieved 7based on observed metrics in patient populations7 under the terms of the agreement2 or 7ii7 a surrogate endpoint 7as defined in section #ejg7;e77#i7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act71 including those developed by patient-focused drug development tools1 that-- 7,i7 is able to be measured or evaluated on an annual basis for each year of the agreement on an independent basis by a provider or other entity2 and 7,,ii7 has been qualified by the ,food and ,drug ,administration4 7,e7 ,risk-sharing value-based payment agreement ,the term risk-sharing value-based payment agreement means an agreement between a ,state plan and a manufacturer-- 7i7 for the purchase of a covered outpatient drug of the manufacturer that is a potentially curative treatment intended for one-time use2 7ii7 under which payment for such drug shall be made pursuant to an installment-based payment structure that meets the requirements of paragraph 7#c72 7iii7 which conditions payment on the achievement of at least #b relevant clinical parameters 7as defined in subparagraph 7,c772 7iv7 which provides that-- 7,i7 the ,state plan will directly reimburse the manufacturer for the drug2 or 7,,ii7 a third party will reimburse the manufacture in a manner approved by the ,secretary2 and 7v7 is approved by the ,secretary in accordance with paragraph 7#b74 7,f7 ,total installment year amount ,the term total installment year amount means1 with respect to a risk-sharing value-based payment agreement for the purchase of a covered outpatient drug and an installment year1 an amount equal to the product of-- 7i7 the unit price of the drug charged under the agreement2 and 7ii7 the number of units of such drug administered under the agreement during such installment year4 4 7b7 ,conforming amendments 7#a7 ,section #aijc7;i77#aj77;,a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acif;b7i77#aj77;,a77 is amended by striking or unless section #aibg7;a77#c7 applies and inserting 1 section #aibg7;a77#c7 applies with respect to such drugs1 or such drugs are the subject of a risk-sharing value-based payment agreement under section #aibg7l74 7#b7 ,section #aibg7;b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;b77 is amended-- 7,a7 in paragraph 7#a77;,a71 by inserting but excluding any drugs for which payment is made by a ,state under a risk-sharing value-based payment agreement under subsection 7l77 after for coverage of such drugs2 and 7,b7 in paragraph 7#c7-- 7i7 in subparagraph 7,c77i71 by inserting or subsection 7l77#b77;,a7 after subparagraph 7,a72 and 7ii7 in subparagraph 7,d71 in the matter preceding clause 7i71 by inserting 1 under subsection 7l77#b77;,a71 after under this paragraph4